Lipid Panel Interpretation Flashcards

A 52-year-old woman has LDL-C 135 mg/dL, HDL-C 42 mg/dL, TG 155 mg/dL, and TC 208 mg/dL. Her 10-year ASCVD risk is 9.8%. According to ACC/AHA guidelines, what is the most appropriate next step?

Answer: Discuss risk-enhancing factors and consider moderate-intensity statin

For intermediate-risk patients (7.5–20% 10-year ASCVD risk), ACC/AHA guidelines recommend a risk discussion incorporating risk-enhancing factors before initiating moderate-intensity statin therapy.

Which of the following best defines the LDL-C treatment goal for a patient with established ASCVD and a recent ACS event (very high-risk)?

Answer: <55 mg/dL

For very high-risk ASCVD patients (including those with recent ACS), 2022 ACC/AHA guidelines recommend an LDL-C goal of <55 mg/dL with a ≥50% reduction from baseline.

A fasting lipid panel shows TC 240 mg/dL, HDL-C 60 mg/dL, TG 100 mg/dL, LDL-C 160 mg/dL. Calculated non-HDL is 180 mg/dL. How does this panel affect ASCVD risk interpretation?

Answer: High HDL-C partially offsets the elevated LDL-C and should be factored into risk assessment

HDL-C ≥60 mg/dL is considered a negative risk factor that partially offsets cardiovascular risk and should be incorporated into overall ASCVD risk assessment alongside other lipid values.

A patient on maximally tolerated statin plus ezetimibe has LDL-C 78 mg/dL with very high-risk ASCVD. Which interpretation is most accurate?

Answer: LDL-C remains above the <55 mg/dL very-high-risk target; PCSK9 inhibitor addition is appropriate

For very high-risk ASCVD patients with LDL-C above 55 mg/dL despite maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is guideline-supported to achieve the LDL-C goal.

Which lipid panel component most directly reflects the number of atherogenic lipoprotein particles when LDL-C and triglycerides are discordant?

Answer: Apolipoprotein B

Apolipoprotein B (apoB) measures the total number of atherogenic lipoprotein particles (each containing one apoB molecule) and provides more accurate risk assessment than LDL-C when there is LDL-TG discordance.

A patient's lipid panel reveals TG 900 mg/dL. The plasma appears milky (lactescent). What is the most immediate concern?

Answer: Risk of acute pancreatitis requiring triglyceride-lowering therapy

Triglycerides above 500–1000 mg/dL (lactescent plasma) carry significant risk of acute pancreatitis, which is the immediate clinical priority requiring urgent intervention with fibrates, omega-3s, and dietary fat restriction.

Lp(a) levels are measured separately from a standard lipid panel. What is the primary clinical reason to order Lp(a)?

Answer: To identify a genetically determined residual ASCVD risk factor not captured by standard lipid panel

Lp(a) is a genetically determined, largely statin-unresponsive lipoprotein that represents an independent ASCVD risk factor, and its measurement identifies residual risk missed by standard lipid panels.